Key regions: United States, Europe, Brazil, Japan, United Kingdom
The Bronchodilator Drugs market in Moldova has been witnessing significant growth in recent years.
Customer preferences: The increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis has led to a rise in demand for bronchodilator drugs in Moldova. Moreover, the aging population and the high levels of air pollution in the country have further contributed to the growth of the market.
Trends in the market: One of the major trends in the Bronchodilator Drugs market in Moldova is the shift towards combination therapies. Combination therapies are becoming increasingly popular as they offer enhanced efficacy and convenience for patients. Another trend in the market is the increasing adoption of digital technologies such as telemedicine and mobile health apps. These technologies are helping to improve patient outcomes and increase access to healthcare services in remote areas.
Local special circumstances: Moldova is one of the poorest countries in Europe, and the healthcare system in the country is underfunded and understaffed. This has led to a shortage of healthcare professionals and a lack of access to healthcare services for many people in the country. Moreover, the regulatory environment in Moldova is relatively weak, which has led to concerns about the quality and safety of some bronchodilator drugs.
Underlying macroeconomic factors: The Moldovan economy has been growing in recent years, but it remains heavily dependent on remittances from migrant workers and exports of agricultural products. The country is also facing significant political instability, which has led to a lack of investment in healthcare infrastructure and a brain drain of healthcare professionals. These factors are likely to continue to impact the Bronchodilator Drugs market in Moldova in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
